Niagen Bioscience, Inc. (NAGE)

Niagen Bioscience Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	116.3	99.6	83.57	72.05	67.45	59.26
Revenue Growth (YoY)	35.89%	19.18%	15.99%	6.82%	13.83%	28.01%
Cost of Revenue	42.31	38.01	32.79	29.25	25.96	23.98
Gross Profit	73.99	61.59	50.78	42.8	41.49	35.27
Selling, General & Admin	51.89	47.84	51.42	56.6	64.73	51.71
Research & Development	5.43	6.02	4.96	4.83	3.83	3.42
Operating Expenses	57.32	53.86	56.38	61.43	68.56	55.13
Operating Income	16.67	7.73	-5.6	-18.63	-27.07	-19.85
Interest Expense	-	-	-	-	-0.06	-0.07
Interest & Investment Income	1.66	1.13	0.66	0	-	-
EBT Excluding Unusual Items	18.33	8.86	-4.94	-18.63	-27.13	-19.93
Other Unusual Items	-	-	-	2.09	-	-
Pretax Income	18.33	8.86	-4.94	-16.54	-27.13	-19.93
Income Tax Expense	0.6	0.31	-	-	-	-
Earnings From Continuing Operations	17.73	8.55	-4.94	-16.54	-27.13	-19.93
Net Income	17.73	8.55	-4.94	-16.54	-27.13	-19.93
Net Income to Common	17.73	8.55	-4.94	-16.54	-27.13	-19.93
Shares Outstanding (Basic)	77	76	75	70	67	61
Shares Outstanding (Diluted)	83	78	75	70	67	61
Shares Change (YoY)	10.13%	4.19%	7.54%	3.79%	10.02%	7.03%
EPS (Basic)	0.23	0.11	-0.07	-0.24	-0.40	-0.33
EPS (Diluted)	0.22	0.11	-0.07	-0.24	-0.40	-0.33
Free Cash Flow	20.93	11.95	6.97	-15.43	-24.57	-10.72
Free Cash Flow Per Share	0.25	0.15	0.09	-0.22	-0.37	-0.18
Gross Margin	63.62%	61.83%	60.76%	59.40%	61.51%	59.53%
Operating Margin	14.33%	7.76%	-6.70%	-25.85%	-40.14%	-33.51%
Profit Margin	15.24%	8.58%	-5.91%	-22.96%	-40.22%	-33.63%
Free Cash Flow Margin	18.00%	11.99%	8.34%	-21.42%	-36.43%	-18.10%
EBITDA	17.45	8.54	-4.57	-17.57	-25.96	-18.74
EBITDA Margin	15.01%	8.58%	-5.47%	-24.39%	-38.48%	-31.62%
D&A For EBITDA	0.78	0.81	1.03	1.06	1.12	1.11
EBIT	16.67	7.73	-5.6	-18.63	-27.07	-19.85
EBIT Margin	14.33%	7.76%	-6.70%	-25.85%	-40.14%	-33.51%
Effective Tax Rate	3.28%	3.44%	-	-	-	-
Advertising Expenses	-	11.1	10.3	11.4	12.5	7.4

Updated May 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q